What Cefepime/enmetazobactam Treats: Main Uses and Benefits

This medication is commonly used to help manage serious bacterial infections in adults, particularly in situations where drug resistance is a concern. It is relevant across domains where additional symptomatic support is needed and is applied in clinical settings that involve acute or unstable symptom patterns.

The primary conditions where this treatment is considered are complicated urinary tract infections (cUTI), including acute pyelonephritis (kidney infection), and severe lung infections such as hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP).

It is applied in contexts marked by increased discomfort or tension caused by resistant bacteria, including ESBL-producing organisms, which supports the patient during difficult episodes and helps maintain a sense of stability. The overall benefit helps provide supportive relief during these difficult episodes, which assists with easing the overall symptom burden.

Quick Fact: Relief for Acute Infection Symptoms
This antibiotic is used to help manage symptoms related to systemic imbalance (like high fever and chills) and localized discomfort (like intense flank pain) in conditions presenting with acute episodes.

Regulatory References

1. European Medicines Agency (EMA) product information

Who Can and Cannot Use Cefepime/enmetazobactam?

The eligibility for Cefepime/enmetazobactam is strictly defined by regulatory guidelines, focusing on absolute contraindications, age, and physiological status.

---

Absolute Contraindications

Cefepime/enmetazobactam must not be used by individuals with a known history of serious hypersensitivity reactions (severe allergy) to either the drug components or to any other beta-lactam antibacterial drugs (including penicillins, other cephalosporins, or carbapenems).

---

Eligibility by Age Group

Age Group	Eligibility Status
Adults (18 years and older)	Approved for use.
Pediatric Population (< 18 years)	Use Not Established. Safety and effectiveness have not been established in this age group.

---

Special Population Restrictions

• Renal Impairment: Patients with reduced kidney function (estimated glomerular filtration rate, or eGFR, below 60 mL/min) require mandatory dosage adjustment. This restriction prevents drug accumulation and the associated risk of neurotoxicity.
• Pregnancy and Lactation: Use is not recommended due to insufficient data on the fixed combination in human subjects. The medicine should only be administered if the benefit to the mother clearly outweighs the potential risk to the fetus or breastfeeding infant.

Cefepime/enmetazobactam has officially documented interaction patterns that are classified based on pharmacokinetic changes and pharmacodynamic effects, as outlined in government regulatory information. Regulatory labels do not cite any specific medicinal products as formally contraindicated for co-administration.

Pharmacokinetic Interactions

The disposition of the cefepime component is affected by agents that interfere with its renal tubular secretion. Co-administration with substances that share this clearance pathway, such as Aminohippurate Sodium, is documented to reduce cefepime's elimination. This interaction results in an increase in the drug’s plasma concentration or systemic exposure. The enmetazobactam component has a low potential for metabolic interaction and is not considered a major inhibitor or inducer of Cytochrome P450 enzymes.

Pharmacodynamic Interactions

Several interactions are classified based on additive or antagonistic effects:

• Organ Toxicity Risk: Concomitant use with Aminoglycoside Antibiotics or Potent Diuretics (e.g., Furosemide) carries an officially noted risk of additive nephrotoxicity, requiring clinical awareness.
• Coagulation Potentiation: Co-administration with Coumarin Anticoagulants may potentiate their action, increasing the potential for a prolonged prothrombin time. This potential is officially noted as heightened in patients with Hepatic Impairment or a Poor Nutritional State.
• Timing Requirement: The antibiotic exhibits pharmacodynamic antagonism with Live Bacterial Vaccines. Regulatory documents mandate a time-based separation from the antibiotic treatment to prevent a diminished therapeutic effect of the vaccine.

Cefepime/enmetazobactam operates through a dual mechanism targeting the structural integrity and enzymatic defenses of bacteria. The core antibiotic, Cefepime, acts by covalently binding to and inhibiting bacterial enzymes known as Penicillin-Binding Proteins (PBPs), which are essential for constructing the peptidoglycan cell wall. This inhibition blocks the final cross-linking step, swiftly compromising the bacterial structure. The resulting physiological consequence is immediate bacterial cell lysis and death (a bactericidal effect).

The second component, Enmetazobactam, engages a mechanism of enzyme protection that addresses resistance. It acts as a mechanism-based inhibitor, irreversibly binding to and neutralizing key bacterial defense enzymes known as beta-lactamases (especially ESBLs). This action prevents the hydrolysis of Cefepime, increasing the concentration of the active antibiotic available at the PBPs. This synergy sustains the bactericidal process against resistant strains. The overall mechanistic effect is, however, constrained and does not extend to bacteria possessing Metallo-beta-Lactamases (MBLs) or non-enzymatic resistance, such as altered porin channels.

Cefepime/enmetazobactam is administered exclusively through intravenous (IV) infusion and is intended for use only in adults, typically in a supervised clinical setting. The drug is supplied as a sterile powder that must be reconstituted and further diluted by a healthcare professional prior to infusion, as the resulting solution is not for direct injection.

Official Dosing and Administration

The standard adult dose is 2.5 grams (comprising 2 g of cefepime and 0.5 g of enmetazobactam). This dose is administered every 8 hours.

The duration of the IV infusion is typically 2 hours, although the administration may be extended to 4 hours for patients identified with high renal clearance. The total length of the treatment course generally ranges from 7 to 14 days.

Administration Constraint	Labeled Instruction
Route and Form	IV Infusion only; requires dilution and reconstitution.
Renal Adjustment	Dosage must be adjusted based on the patient’s estimated Glomerular Filtration Rate (eGFR) if < 60 mL/min.
Dialysis Timing	For patients receiving intermittent hemodialysis, the dose is given after the completion of the dialysis session.

These official instructions establish the precise procedural steps for using Cefepime/enmetazobactam, restricting its use to contexts where controlled, intermittent intravenous delivery over a fixed duration and frequent renal function monitoring can be ensured.

Cefepime/enmetazobactam: Recent Clinical Evidence

Research examined this medicine for use in complicated urinary tract infections (cUTI) and acute pyelonephritis (kidney infection), primarily through a large-scale, randomized controlled trial. These studies monitored outcomes related to systemic or functional imbalance and specifically evaluated a composite study outcome. Researchers applied this drug combination and a pre-defined comparator antibiotic to large groups of hospitalized adults. Research describes patterns where patients receiving Cefepime/enmetazobactam were evaluated against the comparator for symptom resolution and elimination of bacteria, including in cases caused by Extended-Spectrum Beta-Lactamase (ESBL)-producing bacteria.

---

The structure of study types available is different for hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP). The evidence supporting these severe lung infections was evaluated in primary Pharmacokinetic/Pharmacodynamic (PK/PD) studies rather than a dedicated large-scale trial. These studies research examined how the medicine is processed in the body, including the concentration levels observed in the lung fluid of healthy adult volunteers. Regulatory assessment was observed in some studies to consider this modeling data and extrapolation from the clinical results observed in the cUTI population.

---

Follow-up durations were limited in the main clinical trials, meaning long-term effects are not fully established across all indications. Comparative evidence is lacking for a dedicated Phase 3 clinical trial for HAP/VAP, and subgroup findings are uncertain or insufficient for many special populations, including pediatric patients (children), for whom research is ongoing. Research provides context but not individual predictions, and the evidence highlights what is known—and what is still uncertain—about its evaluation in clinical settings.

Common questions about Cefepime/enmetazobactam (FAQ)

Q: Is Cefepime/enmetazobactam considered a broad-spectrum antibiotic?

Regulatory documents indicate that Cefepime, one of the components, is a fourth-generation cephalosporin, which is generally associated with broad-spectrum activity. The addition of enmetazobactam helps this combination specifically target certain types of resistant bacteria that produce enzymes called ESBLs. Official information indicates the drug is intended for use against challenging pathogens that are resistant to some other common antibiotics.

Q: Is it normal to feel a cool sensation at the injection site during the Cefepime/enmetazobactam infusion?

Official safety documents list reactions at the infusion site, such as phlebitis (vein irritation or inflammation), as common effects reported in clinical trials. While a cool sensation is not specifically listed, the location of this feeling aligns with where infusion site reactions, which are common, are typically reported.

Q: Why do official sources mention a risk of Clostridioides difficile (C. diff) infection with this drug?

As with nearly all antibacterial agents, official warnings state that Clostridioides difficile-associated diarrhea (CDAD) has been reported with its use. This risk is due to the antibiotic potentially altering the normal balance of helpful bacteria in the colon. Regulatory documents note that severe diarrhea, especially if watery or bloody, is a symptom associated with CDAD that requires clinical review.

Q: What does it mean if Cefepime/enmetazobactam causes a 'false positive' on a urine test?

Official prescribing information notes that the cefepime component may cause certain laboratory test results to be inaccurate. Specifically, it is associated with a potential for a false-positive reaction for glucose (sugar) in the urine when tested using specific methods, such as Clinitest tablets. This means the test may indicate high sugar levels even if they are normal.

Q: Can taking Cefepime/enmetazobactam interfere with hormonal birth control pills?

Regulatory guidance does not cite a specific contraindication with hormonal birth control pills. However, official information for broad-spectrum antibiotics, as a class, notes a theoretical possibility that they may reduce the effectiveness of oral contraceptives in some individuals. Official labels advise that individuals using hormonal contraceptives should be aware of this general possibility.

Q: Why does the packaging mention potential effects on the ability to drive or use machines?

The inclusion of this warning is related to potential adverse reactions that affect the nervous system, which are documented in safety documents. These effects can include dizziness, confusion, or convulsions. Regulatory warnings are included because these documented effects may temporarily impair functional abilities.

Q: What are 'ESBL-producing Enterobacterales' that Cefepime/enmetazobactam is designed to target?

ESBL stands for Extended-Spectrum Beta-Lactamase. Enterobacterales is a large family of bacteria, including common pathogens like E. coli. These bacteria can develop ESBL enzymes, which break down and neutralize many common antibiotics. Official documents state that the combination is designed to work because the enmetazobactam component helps to prevent the breakdown of the antibiotic by these resistance-causing enzymes.

Q: Is Cefepime/enmetazobactam used to treat community-acquired or hospital-acquired infections?

The drug is indicated for serious infections that may be encountered in both community and hospital settings, such as complicated urinary tract infections. Official information also specifically includes indications for treatment of certain infections acquired within a clinical environment, such as hospital-acquired pneumonia.

Q: Is Cefepime/enmetazobactam considered a 'new' type of antibiotic?

The combination of Cefepime and Enmetazobactam is considered a relatively new antibacterial agent in the field of treatment for resistant pathogens. It has received regulatory approvals in recent years and is recognized for its utility against specific resistant Gram-negative bacteria.

Q: Is diarrhea a common side effect of Cefepime/enmetazobactam, and when is it serious?

Diarrhea is listed in official documents as a common side effect. However, if diarrhea becomes severe, watery, bloody, or persists long after the medication is stopped, it may be associated with the serious risk of Clostridioides difficile-associated diarrhea. Diarrhea that is severe, watery, bloody, or persistent is a symptom that regulatory warnings associate with the need for clinical review.

Q: Can Cefepime/enmetazobactam cause a reaction like a rash or hives?

The drug's safety profile includes documented adverse reactions that affect the immune system, classified as hypersensitivity reactions. These reactions can appear as a mild rash or hives, or in rare cases, as severe, potentially fatal reactions. Regulatory warnings note that caution is warranted for individuals with a history of allergies to similar drug classes due to the potential for hypersensitivity.

Q: Can Cefepime/enmetazobactam cause blood test results to be inaccurate?

Official information indicates the medication has been associated with changes in certain laboratory tests, potentially causing them to be inaccurate. Specifically, it has been noted to cause a false-positive Direct Coombs' test, which is a laboratory screening used to evaluate certain blood conditions.

Q: Is Cefepime/enmetazobactam safe for people with a history of penicillin allergies?

Official documents state that the medicine is strictly contraindicated for individuals with a known history of severe allergy to any beta-lactam drugs, including penicillins. Regulatory labels state caution is warranted due to the documented potential for cross-hypersensitivity.

Q: Is Cefepime/enmetazobactam used differently for older adult patients?

Official documents note that older adult patients may require careful dose monitoring. This is due to the higher likelihood of decreased kidney function in this population, which can increase the risk of certain side effects, particularly neurotoxicity.

Q: Does Cefepime/enmetazobactam pass into breast milk during breastfeeding?

Studies indicate that the cefepime component passes into breast milk in low concentrations. While data on enmetazobactam in human milk is not fully available, official sources indicate that the use of the medicine during lactation requires a clinical assessment to determine if the potential benefit to the mother outweighs the potential risk to the nursing infant.

Q: What are the known risks of Cefepime/enmetazobactam for people with liver disease?

Official prescribing information states that the presence of liver disease or poor nutritional status is a factor that warrants clinical caution, as these conditions may increase the potential for certain serious side effects. Monitoring may be necessary in these circumstances.

Q: Is Cefepime/enmetazobactam being reserved as a 'last resort' antibiotic for certain infections?

Official documents describe the medicine as a 'carbapenem-sparing alternative,' meaning it is an option to avoid using carbapenems, which are often antibiotics of last resort. Regulatory guidance specifies that its use is restricted to treating infections that are proven or strongly suspected to be caused by susceptible bacteria.

The sterile powder for injection must be stored in the refrigerator at 2°C to 8°C (36°F to 46°F) and must not be frozen. To protect the vials from light, they must be stored in the original carton. The product must also be kept out of the sight and reach of children.

Once the powder is reconstituted and further diluted for intravenous infusion, its stability is limited. The prepared solution is stable for up to 12 hours at room temperature (20°C to 25°C) or up to 24 hours if stored under refrigeration. Any unused portion of the solution must be immediately discarded. Disposal of the product and all associated waste must be done in accordance with local regulatory requirements for pharmaceutical waste, and it must not be put into household waste or wastewater.